ArticleFrontiers in pharmacology2025
Modified Zexie decoction improves phlegm-dampness type stage I hypertension by regulating the gut-immune-kidney axis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut microbial-derived metabolites: key players in kidney disease and renal fibrosis.International journal of biological sciences · 2026Review
- An expert narrative review on the mechanisms and therapeutic potential of gut microbiota-derived metabolites in multi-organ crosstalk.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indroduction: Hypertension pathogenesis increasingly implicates gut microbiota-host crosstalk, where immune regulation bridges gut dysbiosis and renal dysfunction. Phlegm-dampness hypertension-a prevalent Traditional Chinese Medicine (TCM) syndrome typified by metabolic, immune, and renal anomalies-demands novel interventions. Modified Zexie Decoction (MZXD), a TCM formula with documented antihypertensive and anti-inflammatory properties, may target the gut-immune-kidney axis. This study investigated MZXD's efficacy in Stage I phlegm-dampness hypertension via this axis. Methods: Thirty Stage I phlegm-dampness hypertension patients received MZXD for 42 days. Pre- and post-treatment measurements included blood pressure, serum immune markers, renal function parameters, gut microbiota, and short-chain fatty acids (SCFAs). Results: MZXD significantly reduced systolic/diastolic blood pressure (P < 0.05). Gut microbiota diversity increased, shifting toward healthy profiles. SCFA levels rose markedly (P < 0.01). Immune markers (P < 0.05) and renal function improved (P < 0.05). Discussion: MZXD alleviates phlegm-dampness hypertension by modulating the gut-immune-kidney axis: enhancing microbial diversity, boosting SCFAs, attenuating inflammation, and improving renal function. This first systematic validation positions MZXD as a promising multi-target therapy. Future studies should explore clinical scalability and mechanistic depth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.